Logo

Luminex Expects Significant Revenue Shortfall in Q1

Apr 02, 2002

NEW YORK, April 2 - Luminex said on Monday that it expects first-quarter financial results to be "significantly" lower than its prior guidance.

With its rejiggered outlook, triggered by continued delays in the commercialization timetables of its customers, Luminex now expects a wider-than-expected first-quarter loss of $.20 to $.23 per share on revenue of $2.2 million to $2.7 million.
 
Luminex said its revenue continues to be bruised by the "lengthy and unpredictable" sales cycle for its products, including its xMAP bioassay technology.

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.